Patent Litigation: Life Sciences

Our clients, many of whom have been with us for decades, trust us to protect them against competitors seeking to invalidate their patents, or to enforce their patents against infringers. They come to us because Venable has one of the largest and most experienced life sciences patent litigation groups among general practice firms in the United States. Our attorneys are dedicated specifically to serving innovator life sciences companies, which is why pharmaceutical developers, biotech innovators, and medical device manufacturers value our advice for their most important matters.

We have decades of experience representing branded pharmaceutical companies to protect and defend their products against premature generic competition. In fact, we have represented branded pharmaceutical companies in defending against generic challengers since the enactment of Hatch-Waxman in 1984, handling well over 100 cases for 30+ companies. We have also secured one of the largest damages awards ever in a pharma patent infringement trial; argued some of the most prominent cases before the Patent Trial and Appeal Board (PTAB), district courts, and the Federal Circuit involving small molecules, biologics, synthetic processes, and medical devices.

Venable's team of 40+ life sciences patent litigation attorneys combine a command of the law with a solid understanding of science, technology, and business strategy. The group includes many attorneys with advanced scientific and medical degrees, and more than 10 attorneys who have first chaired cases through trial and appeal. Whether the issue relates to small-molecule drugs, biologics, cell and gene therapy, novel vaccines, or human cellular and tissue products, we have the technical know-how, experience, and industry knowledge needed to take on the most complex and high-stakes litigation.